Filtered By:
Management: WHO
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 401 results found since Jan 2013.
Allergy and COVID-19
Acta Biomed. 2021 Nov 29;92(S7):e2021522. doi: 10.23750/abm.v92iS7.12402.ABSTRACTThe first cases of as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection have been reported in Wuhan, China in December 2019. The World Health Organization declared the global pandemic in March 2020. Coronavirus disease 2019 (COVID-19) showed high rates of mortality in the adult population, whereas a mild course was observed in childhood. Allergic diseases, characterized by a type-2 polarization of the immune system, were considered one of the major risk factor of severe COVID-19. Large amounts of clinical data and expert o...
Source: Acta Bio-Medica : Atenei Parmensis - November 29, 2021 Category: General Medicine Authors: Maria De Filippo Martina Votto Ilaria Brambilla Riccardo Castagnoli Lorenza Montagna Carlo Caffarelli Fabio Cardinale Michele Miraglia Del Giudice Mariangela Tosca Silvia Caimmi Amelia Licari Gian Luigi Marseglia Source Type: research
What We Know So Far About the New Variant of COVID-19 Raising Alarms Globally
A new variant of SARS-CoV-2 first reported in South Africa is raising alarms for health officials around the world, leading to fresh travel restrictions amid fears it could be resistant to existing vaccines.
Researchers in South Africa conducting genetic analysis of COVID-19 virus cases determined that a new variant, B.1.1.529, had been found in cases in South Africa, Botswana, and a traveler who had traveled from South Africa to Hong Kong, the country’s health minister announced on Nov. 25. The following day, Belgian health officials reported the first case of the new variant discovered in Europe. That same day, the...
Source: TIME: Health - November 26, 2021 Category: Consumer Health News Authors: Alice Park Tags: Uncategorized COVID-19 Source Type: news
Statement on Data Published in PLOS Medicine on Tolerability and Immune Response of Johnson & Johnson Ebola Vaccine Regimen in Adults Living with HIV
NEW BRUNSWICK, N.J., October 29, 2021 – Data published in PLOS Medicine demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), was well tolerated and induced a robust immune response in both healthy adults and adults living with HIV. These findings, alongside Phase 3 data recently published in The Lancet Infectious Diseases, support the potential prophylactic use of the vaccine regimen to protect people at risk of acquiring Ebola. The regimen was granted Marketing Authorisation by the European Commission in July 2020 and Prequalification from th...
Source: Johnson and Johnson - October 29, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson Announces Real-World Evidence and Phase 3 Data Confirming Strong and Long-Lasting Protection of Single-Shot COVID-19 Vaccine in the U.S.
This study compared approximately 390,000 people who received the Company’s single-shot COVID-19 vaccine versus approximately 1.52 million unvaccinated people matched on age, sex, time, three-digit zip code, and comorbidities and predictors for COVID-19 infection severity.This study is a longitudinal cohort design, using robust propensity matching methods to create a comparator cohort to assess real-world VE. All analyses were performed using the Aetion Evidence Platform, which is a scientifically validated software that is also used by regulators, payers, and health technology assessment bodies to assess the safety, eff...
Source: Johnson and Johnson - September 21, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news
Johnson & Johnson Ebola Vaccine Regimen Demonstrated Robust and Durable Immune Response in Adults and Children in Data Published in The Lancet Infectious Diseases
NEW BRUNSWICK, N.J., September 13, 2021 – Data from two papers published in The Lancet Infectious Diseases demonstrated that the Johnson & Johnson (the Company) Ebola vaccine regimen, Zabdeno® (Ad26.ZEBOV) and Mvabea® (MVA-BN-Filo), generated robust humoral (antibody) immune responses in adults and children (ages 1-17) with the immune responses persisting in adults for at least two years. The data also showed that booster vaccination with Ad26.ZEBOV, administered to adults two years after the initial vaccination, induced a strong anamnestic (immune) response within seven days. These findings support the potential p...
Source: Johnson and Johnson - September 13, 2021 Category: Pharmaceuticals Source Type: news
Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
This study is being conducted in the Americas and Europe where different strains of HIV are circulating. Given these differentiating factors and following consultations with the Mosaico study independent Data and Safety Monitoring Board (DSMB), it was decided that the Mosaico study will continue at this time. “We are extremely grateful to the women who volunteered for the Imbokodo study, and to our partners, including the people on the frontlines, all of whom are contributing every day to this enduring quest to make HIV history,” said Paul Stoffels, M.D., Vice Chairman of the Executive Committee and Chief Scientific Of...
Source: Johnson and Johnson - August 31, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news
Specific antibody response of common variable immunodeficiency patients to BNT162b2 COVID-19 vaccination
On March 11, 2020, the World Health Organization declared that coronavirus disease 2019 (COVID-19) was a pandemic.1 Since then, the disease has reached a 1% to 3% estimated overall mortality rate.2 COVID-19 severity ranges from asymptomatic to acute respiratory distress syndrome and possible death due to multiorgan failure.2 Therefore, to ameliorate the resultant poor health and social and economic consequences, prophylactic vaccines were developed. On December 11, 2020, the U.S. Food and Drug Administration issued the first emergency use authorization of Pfizer-BioNTech mRNA vaccine (BNT162b2) for COVID-19 prevention.
Source: Annals of Allergy, Asthma and Immunology - August 2, 2021 Category: Allergy & Immunology Authors: Nizar Abo-helo, Emad Muhammad, Sondus Ghaben-amara, Josef Panasoff, Shai Cohen Tags: Letters Source Type: research
Specific antibody response of patients with common variable immunodeficiency to BNT162b2 coronavirus disease 2019 vaccination
On March 11, 2020, the World Health Organization declared that the coronavirus disease 2019 (COVID-19) was a pandemic.1 Since then, the disease has reached a 1% to 3% estimated overall mortality rate.2 COVID-19 severity ranges from asymptomatic to acute respiratory distress syndrome and possible death owing to multiorgan failure.2 Therefore, to ameliorate the resultant poor health and social and economic consequences, prophylactic vaccines were developed. On December 11, 2020, the US Food and Drug Administration issued the first emergency use authorization of Pfizer-BioNTech (Pfizer Inc, New York City, New York) messenge...
Source: Annals of Allergy, Asthma and Immunology - August 2, 2021 Category: Allergy & Immunology Authors: Nizar Abo-helo, Emad Muhammad, Sondus Ghaben-amara, Josef Panasoff, Shai Cohen Tags: Letters Source Type: research
